Glenmark Pharmaceuticals, USA (Glenmark) announces the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark’s Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories Limited, NDA 209481.

According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio.”